Dynamics of 8G12 competitive antibody in “prime-boost” vaccination of Hepatitis E vaccine
Hepatitis E virus still poses a great threat to public health worldwide. To date, Hecolin® is the only licensed HEV vaccine in China. Total anti-HEV antibody has been used to reflect vaccine induced immune response in clinical trials for the lack of robust HEV neutralizing antibody detection methods...
Main Authors: | Xing Wu, Pan Chen, Huijuan Lin, Yao Su, Xiaotian Hao, Yufeng Cao, Li Li, Fengcai Zhu, Zhenglun Liang |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2017-06-01
|
Series: | Human Vaccines & Immunotherapeutics |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/21645515.2017.1291105 |
Similar Items
-
Safety of hepatitis E vaccination for pregnancy: a post-hoc analysis of a randomized, double-blind, controlled phase 3 clinical trial
by: Guohua Zhong, et al.
Published: (2023-12-01) -
Immunisation of pigs with recombinant HEV vaccines does not protect from infection with HEV genotype 3
by: Lisa Dähnert, et al.
Published: (2024-06-01) -
Current Hepatitis C Vaccine Candidates Based on the Induction of Neutralizing Antibodies
by: Elsa Gomez-Escobar, et al.
Published: (2023-05-01) -
Mechanisms of Hepatitis C Virus Escape from Vaccine-Relevant Neutralizing Antibodies
by: Rodrigo Velázquez-Moctezuma, et al.
Published: (2021-03-01) -
The Neutralizing Antibody Responses of Individuals That Spontaneously Resolve Hepatitis C Virus Infection
by: Vanessa M. Cowton, et al.
Published: (2022-06-01)